Target+-+6-phoaphoglucantate+dehydrogenase+(P.+vivax)

Plasmodium vivax is a protozoal parasite that is the main source of malaria. P. vivax is one of six species of malaria carriers that infect humans. Symptoms include fever, chills, headache, muscular aching and weakness, vomiting, cough, diarrhoea and abdominal pain. According to DNDi (Drugs for Neglected Diseases initiative), malaria kills about one child every 30 seconds. http://tdrtargets.org/targets/view?gene_id=268632
 * Target (protein/gene name):** 6-phosphogluconate dehydrogenase
 * NCBI Gene # or RefSeq#:** 5475141
 * Protein ID (NP or XP #) or Wolbachia#:** PVX_117745 (PlasmoDB)
 * Organism (including strain):** Plasmodium vivax
 * Etiologic Risk Group (see link below):**
 * / Disease Information (sort of like the Intro to your Mini __Research Write__ up):**
 * Link to TDR Targets page (if present):**
 * Link to Gene Database page (NCBI, EuPath databases -e.g. TryTryp, PlasmoDB, etc - or PATRIC, etc.)**
 * Essentiality of this protein:**
 * Gene/Ortholog:** mtu1874 (OG4_10600); **Phenotype:** non-essential; **Source study:** nmpdr
 * Gene/Ortholog:** mtu1142 (OG4_10600); **Phenotype:** essential; **Source study:** nmpdr
 * Gene/Ortholog:** eco1968 (OG4_10600); **Phenotype:** undefined; **Source study:** blattner
 * Gene/Ortholog:** eco1968 (OG4_10600); **Phenotype:** non-essential; **Source study:** gerdes
 * Gene/Ortholog:** eco1968 (OG4_10600); **Phenotype:** non-essential; **Source study:** keio
 * Gene/Ortholog:** eco1968 (OG4_10600); **Phenotype:** non-essential; **Source study:** shigen
 * Gene/Ortholog:** cel16317 (OG4_10600); **Phenotype:** Larval/Adult Lethal/Arrest; **Source study:** neb
 * Gene/Ortholog:** cel16317 (OG4_10600); **Phenotype:** Embryonic Lethal/Arrest; **Source study:** neb
 * Gene/Ortholog:** cel16317 (OG4_10600); **Phenotype:** Embryonic Lethal/Arrest; **Source study:** wormbase
 * Gene/Ortholog:** cel16317 (OG4_10600); **Phenotype:** Larval/Adult Lethal/Arrest; **Source study:** wormbase
 * Gene/Ortholog:** Tb09.211.3180 (OG4_10600); **Phenotype:** significant loss of fitness in bloodstream forms (3 days); **Source study:** alsford
 * Gene/Ortholog:** Tb09.211.3180 (OG4_10600); **Phenotype:** significant loss of fitness in bloodstream forms (6 days); **Source study:** alsford
 * Gene/Ortholog:** Tb09.211.3180 (OG4_10600); **Phenotype:** significant loss of fitness in procyclic forms; **Source study:** alsford
 * Gene/Ortholog:** Tb09.211.3180 (OG4_10600); **Phenotype:** significant loss of fitness in differentiation of procyclic to bloodstream forms; **Source study:** alsford

Is it a monomer or multimer as biological unit**? (make prediction at** @http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html):
 * Complex of proteins?:** No, but the active site may be in chain A or B
 * Druggable Target (list number or cite evidence from a paper/database showing druggable in another organism):** 0.8

http://www.brenda-enzymes.org/php/result_flat.php4?ecno=1.1.1.44
 * *EC#: ** 1.1.1.44
 * Link to BRENDA EC# page:**

__ [] __. http://www.sigmaaldrich.com/catalog/search?interface=All&term=glycylglycine&N=0&mode=match%20partialmax&focus=product&lang=en®ion=US Glycylglycine: Quantity:132.12g Cost:$1,170.00 Supplier: PharmaGrade Catalog: G0674-100G
 * --** Show screenshot of BRENDA enzyme mechanism schematic
 * Enzyme Assay information (spectrophotometric, coupled assay ?, reagents):** continuous spectophotometric rate determination
 * -- link to Sigma (or other company ) page for assay (see Sigma links below)**
 * -- -or link (or citation) to paper that contains assay information**
 * -- links to assay reagents (substrates) pages.**
 * --- List cost and quantity of substrate reagents, supplier, and catalog #**

-- PDB # or closest PDB entry if using homology model: Homology model: PDB 2W8Z w/ lig -- For Homology Model option: Show pairwise alignment of your BLASTP search in NCBI against the PDB Query Coverage: Max % Identities: % Positives Chain used for homology:
 * Structure (PDB or Homology model)**

MTGTCDIGLIGLAVMGQNLSLNIASNGFTIGVYNRTYERTEDTLKKAKEGNLPIQGYETL EQLINNLKKPRKIILLIKAGPAVDETIKNILKHFEEGDIIIDGGNEWYLNTERRITLCEE HKVEYLAMGVSGGEAGARYGCSFMPGGSKYAYDTIKDILEKCSAKVGTSPCVTYIGPRSS GNYVKMVHNGIEYGDMQLISESYLLMKNILNYNNEKLSEVFKKWNEGILNSYLIEITYKI LGKKDELTDNHLVDMILDIAGAKGTGKWTMLEAIERGIPCPTMCAALDARNISAYKQLRV KADSHFSNDMKVNKVEGENLINFEDDLLNALYCCKIISYTQGLFLLKQVSEEMKWNLNLG EISRIWRGGCIIRAVFLDRITNAYKKNEKLDLLFLDEDFAQEMKNKLPSLRKVVQVATKS SIPIPAFSASLAYFQMVTSQNLPLNLVQAQRDYFGSHTYKRVDRDGDFHTIWE TACTTCCAATCC ATG **__ ACCGGCACTTGTGATATCGG __** TCTCATTGGTCTGGCGGTTATGGGTCAGAACCTGTCC CTGAACATCGCCTCTAACGGTTTTACCATCGGTGTTTACAACCGTACCTACGAGCGTACG GAAGATACCCTGAAGAAAGCGAAAGAGGGTAACCTGCCGATCCAAGGTTATGAAACCCTC GAGCAGCTGATCAACAACCTCAAGAAACCGCGTAAAATCATTCTGCTCATCAAAGCGGGT CCGGCGGTTGACGAAACCATTAAGAACATCCTGAAGCACTTTGAGGAAGGCGACATCATC ATCGACGGTGGTAACGAATGGTACCTCAATACCGAACGTCGTATCACTCTGTGCGAAGAG CACAAAGTAGAATACCTGGCGATGGGTGTTTCTGGTGGCGAAGCAGGTGCGCGCTATGGC TGTTCTTTCATGCCGGGTGGCTCCAAATATGCGTATGACACGATCAAAGACATCCTCGAG AAGTGCTCTGCGAAAGTTGGCACGAGCCCTTGCGTAACTTACATCGGTCCTCGTAGCTCT GGTAACTACGTTAAAATGGTTCACAACGGTATCGAATATGGCGATATGCAACTCATCTCC GAGTCTTACCTGCTGATGAAAAACATTCTGAACTACAATAACGAGAAACTGAGCGAAGTA TTCAAAAAATGGAACGAAGGTATCCTCAACTCTTATCTGATCGAAATCACCTATAAGATT CTGGGCAAGAAGGACGAACTCACGGACAACCATCTCGTTGACATGATCCTGGACATCGCG GGTGCTAAGGGTACGGGTAAATGGACCATGCTGGAAGCGATCGAGCGTGGTATCCCGTGC CCGACCATGTGTGCGGCGCTGGACGCCCGTAATATCTCCGCGTATAAACAGCTGCGCGTT AAGGCGGACTCTCATTTTTCTAACGACATGAAGGTTAACAAAGTTGAAGGTGAAAATCTC ATTAACTTTGAAGACGACCTCCTGAATGCGCTGTACTGCTGCAAGATCATTTCTTACACC CAGGGTCTGTTCCTGCTCAAACAGGTTTCTGAAGAGATGAAGTGGAATCTCAATCTGGGT GAAATCTCTCGTATTTGGCGTGGTGGCTGCATCATCCGCGCTGTCTTCCTGGATCGTATT ACTAACGCGTACAAGAAGAATGAAAAGCTCGACCTGCTCTTTCTCGACGAGGATTTCGCG CAGGAAATGAAGAACAAACTCCCGAGCCTGCGTAAAGTTGTTCAAGTTGCGACCAAATCT TCTATCCCGATCCCGGCGTTCAGCGCGTCTCTGGCCTACTTTCAGATGGTGACCTCTCAA AACCTCCCACTGAACCTGGTGCAGGCGCAACGTGACTACTTCGGCTCTCACACGTATAAG CGTGTTGACCGTGACGGT**__GACTTCCATACTATCTGGGAA__** TAA CAGTAAAGGTGGATA source: http://www.idtdna.com/analyzer/Applications/OligoAnalyzer/
 * Current Inhibitors:**
 * Expression Information (has it been expressed in bacterial cells):**
 * Purification Method :**
 * Image of protein (PyMol with features delineated and shown separately):**
 * Amino Acid Sequence (paste as text only - not as screenshot or as 'code'):**
 * length of your protein in Amino Acids:** 473 aa
 * Molecular Weight of your protein in kiloDaltons using the [|Expasy ProtParam] website:** 53372.4
 * Molar Extinction coefficient of your protein at 280 nm wavelength:**
 * TMpred graph Image ** (@http://www.ch.embnet.org/software/TMPRED_form.html). Input your amino acid sequence to it.
 * CDS Gene Sequence (paste as text only):**
 * GC% Content for gene:**
 * CDS Gene Sequence (codon optimized) - copy from output of Primer Design Protocol (paste as text only):**
 * GC% Content for gene (codon optimized):** 49.2%
 * took CDS gene sequence from primer design tails protocol and input into Oligo Analyzer with 0.4uM Oligo concentration, 50mM Na+ concentration, 2mM Mg concentration and 0.3mM dNTP concentration.

Do Not Need this info for Spring (but still copy these lines to your Target page for now) -- Ask a mentor, Dr. B, or a fellow researcher -how to link a GDocs file if you are not sure how to.
 * Primer design results for pNIC-Bsa4 cloning (list seqeunces of all of your ~40 nt long primers):**
 * ( link to DNA Works output text file - **that should be saved in your Google Docs folder after you did the primer design protocol)

Forward primer: 5’ __ TACTTCCAATCCATG __** ACCGGCACTTGTGATAT ** 3’
 * Primer design results for 'tail' primers (this is just 2 sequences):**

Reverse primer: 5’ __ TATCCACCTTTACTGTTA __** TTCCCAGATAGTATGGAAGTC ** 3’